This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Roche Caves on $6.7 Billion Illumina Offer (Update 1)

Stocks in this article: ILMNLIFEJNJGS

Updated to include additional analyst comments, share prices and added data throughout.

NEW YORK ( TheStreet) -- After extending a $5.7 billion January hostile bid for Illumina (ILMN) multiple times in March, Roche has upped its bid for the genomics machinery company by 15% to $6.7 billion -- or $51 a share -- as many investors and analysts expected.

The proposal by Roche is its third hostile bid in the U.S. pharmaceuticals sector after taking a previous $46.8 billion offer for Genentech and a $3 billion bid for Ventana Medical Systems directly to shareholders. With Thursday's offer price increase, Roche has come back to the table with a higher bid in all three instances.

Still, Roche may need to add to its amended offer for Illumina.

"While we were expecting a raised offer, we were not expecting a raised bid so soon after the initial bid. We still anticipate a higher bid, potentially mid-year, to take advantage of anticipated weakness in the space surrounding 2013 National Institute of Health funding," wrote Mizuho Securities analyst Peter Lawson in a note reacting to the bid. Lawson gives Illumina shares a price target of $62.

"We view today's move as the next step, rather than the final step, in the process that we still ultimately believe will lead to a deal... The important question is whether or not the increased bid is enough to bring Illumina to the negotiating table and allow Roche to learn more about Illumina's closely guarded pipeline," noted JPMorgan analyst Tycho W. Peterson, who rated shares "overweight" with a $70 a share price target. Analysts give Illumina an average price target of $55.38, according to consensus estimates polled by Bloomberg.

For investors betting on a bid increase, Roche's new $51 a share offer price represents a relief, as the bid came up against multiple deadlines and Illumina enacted a "poison pill," which could have led to Roche's withdrawal. Investors will have until April 20 to tender their shares, Roche said in a Thursday statement. Separately, Illumina said that shareholders should take no action until the company's board reviews the bid and makes a recommendation.

In previous reviews, Illumina used a fairness opinion analysis by Goldman Sachs to prove to shareholders that the bid was underpriced.

When Roche first announced the offer on Jan. 25, Illumina shares rocketed past the $44.50 initial price to levels over $55 a share. However, as the takeover attempt dragged on, Illumina shares fell below $50 as some lost their confidence that a higher offer would emerge.

In afternoon trading, Illumina shares were up over 4% to $52.05. Year-to-date, Illumina shares are up over 60%, fueled by Roche's takeover interest, more optimism on the market for its genetic sequencing machinery and speculation that other drug giants could bid on the San Diego-based company.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

In a Thursday statement, Roche Chief Executive Severin Schwan said that the company increased its bid as a way to expedite the merger and help with negotiations, which appeared stalled earlier in March. "Based on our discussions with Illumina shareholders we have seen interest to accelerate the takeover process," said Schwan.

Analysts had called the January bid "opportunistic" and "undervalued," with many pointing to a higher eventual bid by Roche or a competing offer by healthcare giants like Siemens Healthcare (SIE) and Johnson & Johnson (JNJ), Abbott Laboratories (ABT) and Becton, Dickinson (BDX).

Risk arbitrage analysts at Makor said that the move was a first step to an eventual $55 a share takeover. In April, Illumina's annual shareholder meeting and Roche's now upped offer price will likely move the bid forward. Roche recently appointed a hostile slate of directors to Illumina's board. "These elections will clearly favor the bid from Roche," wrote Makor analysts, who expect a deal completion by mid-June.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs